Telomerase activity distinguishes between neuroblastomas with poor prognosis

Annals of Oncology, Jun 1999

Background: Treatment of neuroblastoma has remained a major challenge in pediatric oncology because the assessment of the individual prognosis, particularly in disseminated disease is still obscure. Previous studies have correlated clinical outcome with activity levels of telomerase, a cellular reverse transcriptase which has been detected in the majority of human malignant tumors. Patients and methods: In this blind-trial study, a non-radioactive telomeric repeat amplification protocol (TRAP) with an internal telomerase-assay standard was used on an automated laser fluorescence sequencer for the detection and semiquantitative analysis of telomerase activity (TA) in 67 neuroblastomas of all clinical stages from the German Neuroblastoma Trial and 2 ganglioneuromas. TA levels were correlated with event-free and overall survival rates a markers such as MYCN. Results: TA was present in 14 of 69 (20%) samples, including 3 of 22 stage IVS, 8 of 14 stage IV, 1 of 10 stage III, 1 of 7 stage II and 1 of 14 stage I neuroblastomas and 0 of 2 ganglioneuromas. We found a strong statistical correlation of TA and poor clinical prognosis stages. Multivariate analysis revealed TA as an independent prognostic marker. In particular, the analysis of TA in IVS neuroblastomas distinguished two different prognostic groups. Conclusions: Our data suggest that TA in an independent prognostic marker in neuroblastoma which, in combination with other markers such as MYCN, may proof useful in assessing the individual patient's prognosis.

A PDF file should load here. If you do not see its contents the file may be temporarily unavailable at the journal website or you do not have a PDF plug-in installed and enabled in your browser.

Alternatively, you can download the file locally and open with any standalone PDF reader:

https://annonc.oxfordjournals.org/content/10/6/715.full.pdf

Telomerase activity distinguishes between neuroblastomas with poor prognosis

C. Poremba 1 3 H. Willenbring 0 1 3 B. Hero 1 3 H. Christiansen 1 3 K.-L. Schafer 1 3 C. Brinkschmidt 1 3 H. Jiirgens 1 2 3 W. Bocker 1 3 B. Dockhorn-Dworniczak 1 3 0 Department of Pediatrics 1 'Gerhard-Domagk-Institute of Pathology 2 Department of Pediatric Hematology and Oncology, University of Minister, Germany; Departments of Pediatric Hematology and Oncology, ~ University ofKoln, and University of Marburg , Germany 3 B. Dockhorn-Dworniczak, MD, PhD Gerhard-Domagk-Institute of Pathology Westfalische Wilhelms-University Domagkstrasse 17 48149 Minister Germany Summary Background: Treatment of neuroblastoma has remained a major challenge in pediatric oncology because the assessment of the individual prognosis, particularly in disseminated disease is still obscure. Previous studies have correlated clinical outcome with activity levels of telomerase, a cellular reverse transcriptase which has been detected in the majority of human malignant tumors. Patients and methods: In this blind-trial study, a non-radioactive telomeric repeat amplification protocol (TRAP) with an internal telomerase-assay standard was used on an automated laser fluorescence sequencer for the detection and semiquantitative analysis of telomerase activity (TA) in 67 neuroblastomas of all clinical stages from the German Neuroblastoma Trial and 2 ganglioneuromas. TA levels were correlated with event-free and overall survival rates and established prognostic markers such as MYCN. Results: TA was present in 14 of 69 (20%) samples, including 3 of 22 stage IVS, 8 of 14 stage IV, 1of 10 stage III, 1of 7 stage II and 1of 14 stage I neuroblastomas and 0 of 2 ganglioneuromas. We found a strong statistical correlation between the presence of TA and poor clinical prognosis with regard to all tumor stages. Multivariate analysis revealed TA as an independent prognostic marker. In particular, the analysis of TA in IVS neuroblastomas distinguished two different prognostic groups. Conclusions: Our data suggest that TA is an independent prognostic marker in neuroblastoma which, in combination with other markers such as MYCN, may proof useful in assessing the individual patient's prognosis. Introduction Neuroblastoma represents the most common solid extracranial neoplasm of infancy and childhood, accounting for about 7% of all childhood cancers. The most significant predictors of outcome are age and stage, although an assessment of the patient's prognosis solely on the basis of clinical parameters is limited due to diverse biological tumor behavior and subsequent survival rates, even at distinct clinical stages [1]. The heterogeneity of this tumor entity requires cellular and molecular markers in order to distinguish the different biological characteristics. MYCN copy number and loss of heterozygosity for Ip3236 predict poor outcome in all age and stage groups [2-4]. Telomerase activity (TA) has been shown to be a strong indicator of cellular malignancy in virtually all malignant tumors, including neuroblastoma [5, 6]. Telomerase describes a ribonucleoprotein polymerase which uses an internal RNA component as a template to synthesize telomeric DNA directly onto the ends of chromosomes [7, 8]. These repetetive sequences are considered to be important in the protection and replication of chromosomes. Cells without telomerase activity display progressive shortening of telomeric repeats with each cell division, because lagging-strand DNA synthesis at the very end of linear chromosomes cannot be completed, a phenomenon generally referred to as the end-replication problem [9-11]. Telomere shortening contributing to genetic instability is believed to be the primary signal for senescence mediated by tumor suppressor genes, such as p53 and Rb [12-15]. Induction of telomerase activity in cells that have bypassed this control mechanism could give rise to clonal immortality by compensating for the loss of telomeric DNA and thus maintaining telomere length [16-19]. Telomere length has not proven to be a good indicator of malignancy, since both stabilization and extension caused by mechanisms other than telomerase activation have been reported [6, 19-23]. Previous studies proposed that neuroblastomas with low telomerase activity might consist of cells that completely failed to repress telomerase activity during development, whereas tumors with high telomerase activity are likely to be derived from an immortalization event in a single cell [6, 24-26]. This condition renders clinical implications, since high telomerase activity is supposed to be accompanied by several genetic alterations and poor prognosis, whereas low or even absent telomerase activity in neuroblastomas coincides with good prognosis, and eventually, spontaneous regression [6, 26]. Exact prognostic implications on the basis of this two-entity model have so far been hampered by insufficient distinction of activity levels due to positivity for telomerase activity in the vast majority of neuroblastomas [6, (...truncated)


This is a preview of a remote PDF: https://annonc.oxfordjournals.org/content/10/6/715.full.pdf

C. Poremba, H. Willenbring, B. Hero, H. Christiansen, K.-L. Schäfer, C. Brinkschmidt, H. Jürgens, W. Böcker, B. Dockhorn-Dworniczak. Telomerase activity distinguishes between neuroblastomas with poor prognosis, Annals of Oncology, 1999, pp. 715-721, 10/6,